As Valeant Leaves Markets in Suspense, Its Creditors Carry On

Valeant CEO Meets With Top Execs After Medical Leave

Valeant Pharmaceuticals International Inc. is giving its investors plenty to worry about. Even so, investors in its $31 billion of debt have been a relative picture of calm.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.